Autoimmune Epilepsy
Autoimmune epilepsy refers to seizures and epilepsy caused by antibody-mediated inflammation of the central nervous system, most commonly in the setting of autoimmune encephalitis. Immune-related causes of epilepsy have gained significant recognition over the past two decades, driven by the discovery of pathogenic antibodies targeting neuronal surface and intracellular antigens. Early recognition is critical because these seizures are often resistant to conventional antiseizure medications (ASMs) yet may respond dramatically to immunotherapy, fundamentally altering the treatment paradigm from seizure suppression to immune modulation.
Bottom Line
- Prevalence: Autoimmune etiologies account for an estimated 5–7% of all epilepsies and up to 20% of epilepsies of unknown cause; immune-related factors are increasingly recognized as a distinct etiologic category in the ILAE 2017 classification
- Key antibodies: Cell-surface antibodies (NMDA-R, LGI1, CASPR2, GABA-B, GABA-A, AMPA) are most likely to be pathogenic and treatment-responsive; intracellular antibodies (GAD65, ANNA-1/Hu, CV2/CRMP5) are often paraneoplastic with poorer immunotherapy response
- Clinical clues: Subacute onset, rapid progression, drug-resistant seizures, new-onset psychiatric symptoms, cognitive decline, faciobrachial dystonic seizures (LGI1), movement disorders, and autonomic dysfunction should prompt autoimmune workup
- APE2 score: The Antibody Prevalence in Epilepsy and Encephalopathy score ≥4 has 97% sensitivity for predicting positive neural-specific antibodies; validated tool for selecting patients who warrant autoimmune evaluation
- Treatment: First-line immunotherapy (corticosteroids, IVIg, PLEX) should be initiated promptly; second-line agents (rituximab, cyclophosphamide) for refractory cases; response to immunotherapy serves as diagnostic confirmation in seronegative cases
- Long-term management: Many patients require ongoing immunotherapy rather than (or in addition to) chronic ASMs; early treatment is associated with better seizure and cognitive outcomes
Pathophysiology and Antibody Classification
Mechanisms of Antibody-Mediated Seizures
Autoimmune epilepsy arises from pathogenic autoantibodies that disrupt neuronal excitability through several mechanisms: receptor internalization and downregulation (NMDA-R, AMPA), blockade of inhibitory neurotransmission (GABA-B, GABA-A), disruption of voltage-gated potassium channel complexes leading to neuronal hyperexcitability (LGI1, CASPR2), and complement-mediated neuronal injury. The net effect is a shift in the excitatory-inhibitory balance favoring seizure generation. Unlike structural or genetic epilepsies, the underlying pathology is potentially reversible if immunotherapy is initiated before irreversible neuronal damage occurs.
Cell-Surface vs. Intracellular Antibodies
The distinction between cell-surface and intracellular antibody targets has major clinical and therapeutic implications:
| Feature | Cell-Surface Antibodies | Intracellular Antibodies |
|---|---|---|
| Targets | NMDA-R, LGI1, CASPR2, GABA-B, GABA-A, AMPA, DPPX, IgLON5 | GAD65, ANNA-1 (Hu), CV2/CRMP5, amphiphysin, Ma2 |
| Pathogenic mechanism | Antibodies are directly pathogenic — cause receptor internalization, blockade, or complement-mediated damage | T-cell mediated cytotoxicity — antibodies are biomarkers rather than effectors |
| Paraneoplastic association | Variable: NMDA-R (ovarian teratoma in 20–50% of women); GABA-B (50% SCLC); AMPA (70% thymoma/SCLC); LGI1 rarely paraneoplastic | Strongly paraneoplastic: ANNA-1 (SCLC >80%); CV2 (SCLC, thymoma); Ma2 (testicular germ cell tumors) |
| Immunotherapy response | Often excellent, especially with early treatment; >70% improvement with first-line immunotherapy for LGI1 and NMDA-R | Usually limited; neuronal damage is T-cell mediated and often irreversible; tumor removal is primary treatment |
| Prognosis | Generally favorable with prompt immunotherapy; relapse risk requires monitoring | Guarded; depends on tumor status and degree of irreversible neuronal loss |
Key Antibodies and Their Clinical Syndromes
| Antibody | Seizure Prevalence | Characteristic Seizure/Clinical Features | Cancer Association |
|---|---|---|---|
| NMDA-R | 70–80% | Focal → generalized seizures; psychiatric symptoms (psychosis, agitation); orofacial dyskinesias; autonomic instability; decreased consciousness; young women predominantly | Ovarian teratoma (20–50% of women); rare in men and children |
| LGI1 | >90% | Faciobrachial dystonic seizures (FBDS) — pathognomonic brief (<3 sec), frequent (up to 100/day) dystonic contractions of face and ipsilateral arm; mesial temporal seizures; hyponatremia (60–70%); cognitive decline | Rare (<5%); thymoma reported |
| CASPR2 | 30–50% | Focal seizures; Morvan syndrome (neuromyotonia + encephalitis + autonomic dysfunction + insomnia); limbic encephalitis; peripheral nerve hyperexcitability | Thymoma (20–30%); older males predominate |
| GABA-B | >90% | Early prominent seizures, often refractory; limbic encephalitis; status epilepticus common; older adults | SCLC (~50%) |
| GABA-A | >90% | Refractory status epilepticus; multifocal cortical-subcortical MRI T2/FLAIR abnormalities; rapidly progressive encephalopathy | Thymoma (occasional); often non-paraneoplastic |
| AMPA | 40–60% | Limbic encephalitis; seizures and memory impairment; relapsing course common | Thymoma, SCLC, breast (~70%) |
| GAD65 | Variable | Drug-resistant temporal lobe epilepsy; stiff-person spectrum; cerebellar ataxia; typically high titers (≥20 nmol/L); overlap with type 1 diabetes at low titers | Rarely paraneoplastic |
Faciobrachial Dystonic Seizures (FBDS) — A Diagnostic Hallmark
- Virtually pathognomonic for LGI1 antibody encephalitis
- Brief (<3 seconds), very frequent (up to 50–100 episodes per day) dystonic posturing of the face and ipsilateral arm
- Often precede the onset of cognitive decline by weeks to months — early recognition provides a critical treatment window
- Typically resistant to ASMs but respond rapidly to immunotherapy (corticosteroids or IVIg)
- May be misdiagnosed as myoclonus, tics, or non-epileptic events due to their brevity and EEG may be normal in >50%
- Prompt immunotherapy for FBDS may prevent progression to full limbic encephalitis with cognitive impairment
Clinical Clues Suggesting Autoimmune Etiology
When to Suspect Autoimmune Epilepsy
Several clinical features, alone or in combination, should raise suspicion for an autoimmune etiology. The mnemonic "NORSE-like" features can help clinicians identify high-risk presentations:
- Subacute onset: New-onset seizures or rapid escalation of seizure frequency over days to weeks, particularly in a previously healthy individual
- Drug resistance: Seizures refractory to two or more appropriately chosen and dosed ASMs, especially when drug resistance develops early in the disease course
- Associated neurological features: Cognitive decline, psychiatric symptoms (psychosis, personality change), movement disorders, autonomic dysfunction, or sleep disturbance accompanying seizures
- MRI abnormalities: Unilateral or bilateral mesial temporal T2/FLAIR hyperintensity without alternative structural explanation; multifocal cortical abnormalities (GABA-A)
- CSF pleocytosis: Lymphocytic pleocytosis and/or oligoclonal bands in the absence of infection
- Personal or family history: Other autoimmune conditions (thyroid disease, type 1 diabetes, celiac disease)
- Specific seizure semiologies: FBDS (LGI1), new-onset temporal lobe seizures in adults without structural lesion
APE2 Score: Antibody Prevalence in Epilepsy and Encephalopathy
The APE2 score is a validated clinical tool developed at the Mayo Clinic to identify patients with epilepsy who are likely to have neural-specific autoantibodies and therefore warrant autoimmune evaluation. An APE2 score ≥4 should prompt comprehensive autoantibody testing.
| Clinical Feature | Points |
|---|---|
| New-onset seizure (onset within 1 year of evaluation) | +1 |
| Neuropsychiatric changes (cognitive or behavioral) | +1 |
| Autonomic dysfunction | +1 |
| Viral prodrome | +2 |
| Faciobrachial dystonic seizures | +3 |
| Facial dyskinesias or orolingual dyskinesias | +2 |
| Refractory status epilepticus (no prior epilepsy history) | +2 |
| CSF findings (inflammatory: pleocytosis, elevated protein, or oligoclonal bands) | +2 |
| Brain MRI suggesting autoimmune encephalitis (T2/FLAIR mesial temporal hyperintensity) | +2 |
| History of autoimmune disease (personal) | +1 |
| Total score ≥4: Autoimmune evaluation recommended | — |
APE2 Score Performance
- APE2 ≥4 has 97% sensitivity and 14% specificity for predicting positive neural-specific antibodies — excellent screening tool with high negative predictive value
- The related RITE2 score ≥7 has 93% sensitivity and 60% specificity for predicting seizure responsiveness to immunotherapy
- When APE2 ≥4 is combined with a good response to immunotherapy, the diagnostic accuracy improves significantly: 78% sensitivity, 81.4% specificity, and 88.1% positive predictive value for autoimmune encephalitis
- Patients with epilepsy of unknown etiology and APE2 ≥4 but negative autoantibodies are candidates for a diagnostic trial of immunotherapy
Diagnostic Classification
Levels of Diagnostic Certainty
Autoimmune epilepsy can be classified into three levels of diagnostic certainty based on antibody status, clinical features, and treatment response:
- Definite autoimmune epilepsy: Epilepsy of unknown etiology + APE2 ≥4 + positive neural-specific antibody clinically validated to be associated with autoimmune epilepsy (e.g., LGI1, NMDA-R, GABA-B, CASPR2)
- Probable autoimmune epilepsy: Epilepsy of unknown etiology + APE2 ≥4 + negative autoantibody evaluation + clinical response to immunotherapy
- Possible autoimmune epilepsy: Epilepsy of unknown etiology + APE2 ≥4 + negative autoantibody evaluation + immunotherapy not yet attempted or inconclusive response
Diagnostic Workup
Recommended Evaluation
A systematic approach is required when autoimmune epilepsy is suspected. Testing should be performed before immunotherapy is initiated whenever possible, as treatment may reduce antibody titers and decrease diagnostic sensitivity.
| Test Category | Specific Tests | Key Considerations |
|---|---|---|
| Serum antibodies | Autoimmune encephalitis panel: NMDA-R, LGI1, CASPR2, GABA-B, GABA-A, AMPA, DPPX; GAD65 (quantitative); ANNA-1 (Hu), CV2/CRMP5, Ma2, amphiphysin | Cell-based assays have higher sensitivity for surface antibodies than immunohistochemistry alone; some antibodies (NMDA-R) are more reliably detected in CSF than serum |
| CSF antibodies | Same panel as serum, plus oligoclonal bands, IgG index, cytology | CSF testing is essential — NMDA-R antibodies may be negative in serum but positive in CSF in up to 15% of cases; intrathecal antibody synthesis (elevated CSF:serum ratio) supports autoimmune diagnosis |
| CSF routine | Cell count, protein, glucose, cultures, viral PCR (HSV, VZV) | Lymphocytic pleocytosis (10–100 cells) common in autoimmune encephalitis; must exclude infectious encephalitis (especially HSV, which can trigger NMDA-R antibody production) |
| Brain MRI | Epilepsy protocol with coronal FLAIR through temporal lobes; gadolinium | Mesial temporal T2/FLAIR hyperintensity (LGI1, GABA-B); multifocal cortical lesions (GABA-A); may be normal in up to 50% of autoimmune encephalitis cases |
| EEG | Continuous video-EEG monitoring if acute encephalopathy; routine EEG otherwise | Extreme delta brush pattern (NMDA-R); temporal epileptiform discharges; may detect subclinical seizures in encephalopathic patients |
| Cancer screening | CT chest/abdomen/pelvis; PET-CT; pelvic ultrasound/MRI (ovarian teratoma); testicular ultrasound | Mandatory in all patients with autoimmune encephalitis; guided by antibody type; repeat imaging at 6–12 months if initial screening is negative and cancer-associated antibody is present |
Diagnostic Pitfalls
- Post-HSV NMDA-R encephalitis: NMDA-R antibodies can develop 2–6 weeks after herpes simplex encephalitis due to exposure of neuronal antigens during viral-mediated tissue destruction — always test for HSV before attributing symptoms solely to autoimmune encephalitis
- Low-titer GAD65: Titers <20 nmol/L are commonly found in type 1 diabetes and are not specific for autoimmune epilepsy; only high titers (≥20 nmol/L, or ≥100-fold above normal) are clinically meaningful
- Seronegative autoimmune epilepsy: Up to 40–50% of suspected autoimmune epilepsy cases may be antibody-negative; does not exclude the diagnosis — novel antibodies continue to be discovered; consider empiric immunotherapy trial if clinical suspicion is high (APE2 ≥4)
- Timing of testing: Initiation of immunotherapy before antibody testing may cause false-negative results; obtain samples before treatment whenever clinically feasible
- Paraneoplastic syndromes: Cancer screening should not be abandoned after a single negative evaluation; repeat at 6-month intervals for at least 2 years in patients with high-risk antibody profiles (ANNA-1, CV2, GABA-B)
Treatment
Immunotherapy Approach
The treatment of autoimmune epilepsy fundamentally differs from conventional epilepsy management. While ASMs may partially control seizures, immunotherapy targets the underlying cause. Early initiation of immunotherapy is associated with better outcomes. The 2022 international consensus recommends initiating immunotherapy within 72 hours of suspected autoimmune status epilepticus.
First-Line Immunotherapy
| Agent | Dosing | Onset of Effect | Key Considerations |
|---|---|---|---|
| IV methylprednisolone | 1 g/day (adults) or 20–30 mg/kg/day (max 1 g) for 3–5 days; followed by oral prednisone taper (1 mg/kg/day, taper over 3–6 months) | Days to weeks | Most commonly used first-line agent; hyperglycemia, insomnia, psychiatric effects are common acute side effects; steroid-related exacerbation of seizures is rare but reported |
| IVIg | 0.4 g/kg/day for 5 days (total 2 g/kg); may repeat monthly | 1–3 weeks | Alternative or adjunct to steroids; well-tolerated; risk of aseptic meningitis, headache, thrombosis; check IgA levels before first infusion (anaphylaxis risk in IgA deficiency) |
| Plasma exchange (PLEX) | 5–7 exchanges on alternate days | Days to 1–2 weeks | Rapidly removes circulating antibodies; requires central or large-bore peripheral IV access; most effective for cell-surface antibodies; consider as first-line in severe/fulminant presentations |
Second-Line Immunotherapy
Second-line agents are indicated when first-line therapy fails, for relapsing disease, or as steroid-sparing maintenance therapy. They should be considered within 7 days of onset in refractory cases:
- Rituximab: 375 mg/m2 weekly ×4 or 1000 mg ×2 doses (2 weeks apart); B-cell depletion within 2–4 weeks; recommended as first second-line agent if a pathogenic antibody is identified; retreatment guided by CD19/CD20 cell recovery or clinical relapse; PML risk extremely low
- Cyclophosphamide: IV pulse 750 mg/m2 monthly for 3–6 months; reserved for severe or rituximab-refractory cases; significant toxicity (cytopenias, hemorrhagic cystitis, gonadal toxicity, secondary malignancy); fertility preservation counseling required
- Mycophenolate mofetil: 1000–1500 mg twice daily; slower onset (2–3 months); used for long-term steroid-sparing maintenance; teratogenic
- Azathioprine: 2–3 mg/kg/day; onset 3–6 months; check TPMT genotype; alternative steroid-sparing agent
- Tocilizumab (anti-IL-6): Emerging evidence in refractory autoimmune encephalitis and NORSE/FIRES; 8 mg/kg IV every 4 weeks; may be effective when first- and second-line agents fail
Immunotherapy as Diagnostic Confirmation
In seronegative patients with high clinical suspicion (APE2 ≥4), a therapeutic trial of immunotherapy can serve as a diagnostic tool. Improvement in seizure frequency, cognition, or EEG abnormalities following immunotherapy supports the diagnosis of probable autoimmune epilepsy. The trial should be of adequate duration (at least 3–6 months) and may include escalation through first-line and second-line agents before concluding that the condition is not immune-mediated.
ASM vs. Immunotherapy: Long-Term Management
Balancing Seizure Suppression and Immune Modulation
A unique challenge in autoimmune epilepsy is determining the appropriate balance between ASMs and immunotherapy over the long term:
- Acute phase: Both ASMs and immunotherapy are typically used concurrently; ASMs provide symptomatic seizure control while immunotherapy addresses the underlying cause
- Maintenance phase: If seizures resolve with immunotherapy, gradual ASM withdrawal may be attempted after 1–2 years of seizure freedom, under close monitoring with EEG surveillance
- Immunotherapy duration: No consensus on optimal duration; most experts recommend continuing immunotherapy for at least 1–2 years in antibody-positive cases; relapse rate following immunotherapy withdrawal ranges from 10–35% depending on the antibody
- NMDA-R encephalitis: Relapse rate ~12–25%; risk factors include no first-line treatment, no second-line treatment, and no tumor removal; chronic immunosuppression with mycophenolate or azathioprine reduces relapse risk
- LGI1 encephalitis: Relapse rate ~20–35%; most relapses occur during steroid taper; many patients require prolonged low-dose immunosuppression
- GAD65-associated epilepsy: Generally poor response to immunotherapy; chronic ASMs usually required; best outcomes reported with early aggressive immunotherapy before hippocampal atrophy develops
Practical Treatment Algorithm
- Step 1: Suspect autoimmune etiology → obtain serum and CSF autoimmune panels + MRI + EEG + cancer screening
- Step 2: While awaiting results, initiate first-line immunotherapy (IV methylprednisolone ± IVIg or PLEX) if clinical suspicion is high and seizures are refractory or encephalopathy is progressing
- Step 3: Assess response at 2–4 weeks; if inadequate improvement, escalate to second-line immunotherapy (rituximab preferred)
- Step 4: If antibody-positive, initiate long-term immunosuppressive maintenance and address any underlying malignancy
- Step 5: Taper ASMs cautiously after sustained seizure freedom (≥1 year); continue immunotherapy for ≥1–2 years; monitor for relapse
Treatment Considerations
- Do not delay immunotherapy while awaiting antibody results in patients with rapidly progressive encephalopathy, refractory status epilepticus, or high clinical suspicion — early treatment is associated with significantly better outcomes
- Tumor removal is essential when a paraneoplastic etiology is identified; immunotherapy alone is often insufficient without addressing the tumor
- Intracellular antibody syndromes (ANNA-1, CV2) have limited immunotherapy response — focus on tumor treatment and symptomatic seizure management with ASMs
- Monitor for immunotherapy complications: Infections (especially with rituximab and cyclophosphamide), infusion reactions, steroid-related metabolic effects, progressive multifocal leukoencephalopathy (extremely rare with rituximab)
Specific Clinical Scenarios
Autoimmune Temporal Lobe Epilepsy
New-onset temporal lobe epilepsy in adults without a structural lesion on MRI should prompt consideration of an autoimmune etiology. LGI1 and GAD65 antibodies are the most common causes. Key distinguishing features from mesial temporal sclerosis-associated epilepsy include subacute onset, bilateral temporal involvement, associated cognitive decline disproportionate to seizure frequency, and hyponatremia (LGI1). Early hippocampal swelling on MRI (FLAIR hyperintensity) may progress to hippocampal atrophy if untreated, resembling acquired mesial temporal sclerosis.
Autoimmune Status Epilepticus
Autoimmune etiologies account for 20–40% of new-onset refractory status epilepticus (NORSE). GABA-A and GABA-B antibodies are particularly associated with refractory status epilepticus. Aggressive immunotherapy should be initiated early alongside standard ASM management. The 2022 international consensus recommends immunotherapy within 72 hours and second-line immunotherapy within 7 days for cryptogenic refractory status epilepticus.
Hashimoto Encephalopathy (Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis)
Anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies are sometimes found in patients with encephalopathy and seizures. However, these antibodies are common in the general population (10–15% prevalence) and are not specific for CNS disease. The diagnosis is one of exclusion, and the dramatic response to corticosteroids is a key diagnostic feature. Many cases may actually represent undetected cell-surface antibody-mediated encephalitis.
Outcomes and Prognosis
Outcomes in autoimmune epilepsy depend heavily on the antibody type, rapidity of diagnosis, and timing of immunotherapy initiation:
- NMDA-R encephalitis: ~80% achieve good functional outcome (mRS ≤2) with treatment; median time to improvement is 4–8 weeks; recovery may continue for up to 2 years; cognitive deficits (especially executive function) may persist
- LGI1 encephalitis: >80% respond to first-line immunotherapy; however, ~65% develop chronic cognitive impairment (especially memory) and ~30% develop chronic epilepsy despite immunotherapy
- GABA-B encephalitis: Seizure response to immunotherapy is often good, but overall prognosis is influenced by the high rate of underlying malignancy (~50% SCLC)
- GAD65-associated epilepsy: Most resistant to immunotherapy; chronic drug-resistant epilepsy is common; best outcomes with early aggressive immunotherapy before irreversible hippocampal damage
References
- Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 2018;83(1):166–177.
- Dubey D, Singh J, Britton JW, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia 2017;58(7):1181–1189.
- Bien CG, Holtkamp M. Autoimmune epilepsy: encephalitis with autoantibodies for neurologists. Epilepsy Curr 2017;17(3):134–141.
- Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med 2018;378(9):840–851.
- Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15(4):391–404.
- Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede LGI1 antibody limbic encephalitis. Ann Neurol 2011;69(5):892–900.
- Toledano M, Britton JW, McKeon A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014;82(18):1578–1586.
- de Bruijn MAAM, Bastiaansen AEM,"; Thijs RD, et al. Antibody prevalence in epilepsy and encephalopathy score: increased immunotherapy utilization and improved outcome. Neurology 2022;98(11):e1167–e1178.
- Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512–521.
- Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12(2):157–165.
- Finke C, Pruss H, Heine J, et al. Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol 2017;74(1):50–59.
- Falip M, Rodriguez-Bel L, Casasnovas C, et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol 2012;19(6):827–833.